• Boucherville

Boucherville, Quebec, Canada

Avara’s sterile manufacturing facility and adjacent Center of Excellence for development in Boucherville, Quebec were acquired from Novartis in 2018. The manufacturing facility is the largest sterile injectables plant in Canada and has a 30-year track record as a dependable single source of supply for a portfolio of medically-necessary drugs in the US and Canada. Boucherville currently supplies approximately 175 injectable SKUs to US, Canadian, European and Japanese markets.

With our world-class Center of Excellence for development of sterile injectables next door, Avara is able to provide a full range of analytical, process and formulation development services, as well as project management, clinical development, regulatory and quality support.

Capabilities

Boucherville_Capabilities2

Development / Labratory

  • Research and development
  • Analytical method development, transfer and validation
  • Material characterization
  • Particle characterization
  • Process and formulation development
  • Product development
  • Project management
  • Clinical development
  • Regulatory affairs
  • Quality control microbiology
  • Quality control chemistry

Manufacturing

  • Aseptic filling of vials and ampoules
  • 20L to 1200L batch sizes
  • Terminal sterilization of vials and ampoules

Packaging

  • Single and multi-vial/ampoule packaging
  • Multi-pack cartoning of vials and ampoules
  • High-volume automated packaging
  • Manual packaging
  • High-volume automated labelling
  • Multi-country/language labelling, finishing and serialization
  • Anti-mix/counterfeit controls
  • Vial inspection

Warehousing

  • Grade 4
  • 30,000 square feet
  • 3 controlled substances vaults (level 9 and 10)
  • 4 cold rooms (2C to 8C)
  • 4 freezers (-20 to -30)
  • 1 flammable material vault
  • 2 label rooms
  • Cold chain management
  • Warehouse management system SAP radio frequency (qualified)
  • HVAC system coverage throughout

Locations